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CObjective: Within a health-care decision-making context, whose
health state utility values (HSUVs) should be used is constantly de-
bated. This discussion is important because patient and general popu-
lation utilities can differ. These discrepancies may be due to the gen-
eral population not being informed about the health states. This article
investigates approaches used to inform the general population about
the health states that they are valuing. Methods: Studies reporting
methods to obtain informed general populationHSUVswere identified,
outlined, and critically appraised.Results: Fourteen studieswere iden-
ified: seven used information sessions, two used simulationmethods,
wo used reflection and deliberation techniques, and three used adap-
ation exercises. Conclusions: This review demonstrated a range of O
Cent
al So
doi:10.1016/j.jval.2011.05.046pproaches to elicit informed general population HSUVs. Themajor-
ty of the studies indicated that informing the respondents signifi-
antly affected their opinions of the health states and hence their
SUVs. This suggests that the utilities that are currently used to
uide health-care resource allocation decisions may not represent
he general population’s preferences for specific health states. This
ould result in decisions that do not maximize societal health
enefits.
eywords: adaptation, general population, health states, informed
tilities, review.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Cost-utility analysis (CUA) is increasingly being used to guide de-
cisionmakers regarding the allocation of health-care resources. In
CUA, health benefits are quantified using quality-adjusted life-
years (QALYs) [1], a measure that combines both duration and
uality of life (QOL) into a single index. QOL information is obtain-
ble from respondents in the form of health state utility values
HSUVs). Whether patients or members of the general population
hould provide HSUV to be incorporated into a CUA is currently
nder debate [2].
Although patientsmay be better at valuing their ownhealth [3],
most agencies that use QALYs have advocated that HSUVs should
be obtained from the general population [4–6]. This is because
general population utilities are better suited to inform policy de-
cisions in publicly funded health-care systems. Rational citizens,
operating behind a “veil of ignorance,” provide HSUVs unbiased by
specific interests. General population respondents are asked to
envision life in the health state and then provide a utility value for
it. A drawback to using general populationHSUVs, however, is that
health state descriptions are brief. As such, respondents may not
fully comprehend life with the impaired health state, leading to
decisions that do not maximize societal health benefits.
The debate on whose HSUVs to use is important because pre-
vious studies have shown significant discrepancies between pa-
tient and general population utilities [7,8]. Generally, patient util-
ities tend to be higher than those of the general population’s. This
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1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.may be a result of misinterpreting the same health state or incor-
porating differing levels of disease adaptation into the valuations;
for a further discussion, refer to Ubel et al. [9], Brazier et al. [10],
and Stiggelbout and de Voel-Voogt [11]. This difference can have
significant ramifications when incorporated into a CUA [9].
To ensure that general population utilities are relevant, HSUVs
provided by respondents informed about the health condition
may be a better approach [4,10,12]. The informing process allows
the respondents to incorporate all available information regarding
the health condition into their own assessment. Thus, the current
challenge is to refine the health state elicitationmethod such that
respondents are informed and able to formulate their HSUVs. This
article synthesizes the results from studies that informed the gen-
eral population when valuing health states.
Methods
PubMed, EMBASE, and PsycINFO databases were searched to iden-
tify empirical studies that informed the general population about
the health states that they are valuing. The search was restricted
to articles in English dated 2009 or earlier. The search keywords
were general population, public, health state$, inform$, and utility. The
references of retrieved articles were searched to trace potentially
relevant articles.
Peer-reviewed published studies were selected for review if
they used written or other audiovisual techniques to describe the
re for Applied Research in Cancer Control, 675 West 10th Avenue,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
Table 1 – Characteristics of the reviewed studies.
No. Study Design Sample Country of
study
Control
group
Pre- and
posttests
Health state valued Valuation method Mean informed HSUVs
Type Size Pretest Posttest Control
Information to enrich the health state descriptions
1 Bramlett et al., 2006 [16] SI GP (r) 75 US No No Mild stuttering SG N/A 0.96 N/A
TTO 0.93
Rating 0.80
Moderate stuttering SG 0.91
TTO 0.85
Rating 0.65
Severe stuttering SG 0.81
TTO 0.63
Rating 0.44
2 Briggs et al., 2008 [17] SI GP (c) 75 UK No No Stable schizophrenia TTO N/A 0.87 N/A
Relapsed schizophrenia TTO 0.48
3 Clarke et al., 1997 [18] SI GP (c) 39 Canada, US Yes (patient) No Gaucher’s disease (low blood
counts)
SG N/A 0.94 0.94
TTO 0.87 0.87
Risk-risk trade-off 0.32 0.55
Gaucher ‘s disease (bone pain) SG 0.94 0.81
TTO 0.86 0.81
Risk-risk trade-off 0.29 0.40
Gaucher ‘s disease (enlarged
abdomen)
SG 0.92 0.90
TTO 0.82 0.80
Risk-risk trade-off 0.24 0.45
4 Cunningham and Hunt,
2000 [19]
SI GP (c) 57 UK Yes No Dentofacial deformities SG N/A 0.73 0.79
TTO 0.67 0.72
VAS 54.3 59.5
5 Happich and von
Lengerke, 2005 [20]
SI GP (r) 210 Germany Yes (patient) No Tinnitus SG N/A 0.81 0.80
TTO 0.79 0.77
VAS 0.34 0.35
6 Lee et al., 2000 [21] SI GP (r) 20 USA Yes (patient) No Mild schizophrenia SG N/A 0.88 0.92
VAS 0.64 0.70
Moderate schizophrenia SG 0.83 0.92
VAS 0.54 0.64
7 Lenert et al., 2004 [22] SI GP (c) 620 USA No No Mild schizophrenia SG N/A 0.88 N/A
Moderate schizophrenia (type 1) SG 0.76
Moderate schizophrenia (type 2) SG 0.75
Severe schizophrenia (type 1) SG 0.65
Severe schizophrenia (type 2) SG 0.66
Severe schizophrenia (type 3) SG 0.56
Severe schizophrenia (type 4) SG 0.63
Extremely severe SG 0.43
Simulation to reproduce symptoms of the health state descriptions
8 Aballéa and Tsuchiya,
2007 [23]
SI GP (r) 38 UK No No Mild visual impairment TTO N/A 0.76 N/A
Severe visual impairment TTO 0.50
Postoperative vision TTO 0.55
(continued on next page)
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Table 1 (continued).
No. Study Design Sample Country of
study
Control
group
Pre- and
posttests
Health state valued Valuation method Mean informed HSUVs
Type Size Pretest Posttest Control
9 Czoski-Murray et al.,
2009 [24]
SI GP (c) 104 UK No No Reading limit TTO N/A 0.71 N/A
Legal blindness TTO 0.59
Untreated age-related macular
degeneration
TTO 0.36
Reflection and deliberation techniques
10 Shiell et al., 2003 [25] SI GP (r) 233 Australia Yes Yes EQ-5D state 11222 SG 0.71 0.68 0.66
TTO 0.75 0.72 0.61
EQ-5D state 11213 SG 0.58 0.53 0.57
TTO 0.55 0.53 0.52
11 Stein et al. 2006, [26] SI GP (c) 15 UK No Yes Multiple sclerosis state 1 SG 0.75 0.83 N/A
Multiple sclerosis state 2 SG 0.94 0.93
Gaucher’s disease SG 0.88 0.88
EQ-5D state 1 SG 0.97 0.98
EQ-5D state 2 SG 0.30 0.30
EQ-5D state 3 SG 0.75 0.75
Heart failure state 1 SG 0.84 0.84
Heart failure state 2 SG 0.51 0.50
Moderate eczema SG 0.782 0.786
Severe eczema SG 0.70 0.69
Osteoarthritis state 1 SG 0.96 0.96
Osteoarthritis state 2 SG 0.83 0.83
Osteoarthritis state 3 SG 0.96 0.97
Osteoarthritis state 4 SG 0.98 0.98
Exercises to evoke adaptation to the health states
12 Damschroder et al.,
2005 [27]
SQ GP (c) 359 USA Yes No Preexisting paraplegia PTO N/A Saving the lives of 100
patients  saving
the lives of 100
healthy people
Saving the lives of 100
patients  saving the
lives of 102 healthy
people
New-onset paraplegia PTO Saving the lives of 102
patients  saving
the lives of 100
healthy people
Saving the lives of 1000
patients  saving the
lives of 100 healthy
people
13 Damschroder et al.,
2008 [28]
SI GP (r) 1117 USA No Yes Below-the-knee amputation SG N/A 0.76 0.76
TTO 0.89 0.90
Severe back pain SG 0.73 0.72
TTO 0.83 0.86
Colostomy SG 0.64 0.67
TTO 0.81 0.81
Paraplegia SG 0.63 0.67
TTO 0.79 0.80
14 Ubel et al., 2005 [29] SQ GP (c) 852 USA Yes Yes Paraplegia VAS 47.0 51.6 62.2
698 Paraplegia VAS 50.6 58.5 52.7
EQ-5D, EuroQoL; GP (c), general population (convenient sample); GP (r), general population (representative sample); HSUVs, health state utility values; N/A, not applicable; PTO, person trade-off; SG,
standard gamble; SI, structured interview; SQ, self-completed questionnaire; TTO, time trade-off; VAS, visual analog scale. 1155
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1156 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 5 3 – 1 1 5 7health states to the respondents. Studies were excluded if the re-
spondents did not value distinct health states. After a critical re-
view of titles and abstracts, 14 full-text articles met the inclusion
criteria. Extracted information included design, type of sample
and size, country of study, presence of a control group, pre- and
post-tests used, health state labels, valuation techniques used,
and mean informed HSUVs.
Results
Table 1 summarizes the identified empirical studies. Interventions
used to inform the general populationwere categorized into infor-
mation to enrich the health state descriptions (n  7); simulation
to reproduce the symptoms of the health state (n 2); opportunity
to reflect and deliberate on the health state descriptions (n  2);
nd exercises to evoke adaptation to the health state (n 3). More
information about the reviewed studies is available in Appendix A
found at doi: 10.1016/j.jval.2011.05.046.
The majority of the identified studies provided respondents
with additional information through the use of audio recordings
and videos. The drawback of this approach is that the respondents
are not able to properly envision themselves in the health state
that they are being asked to value. One method to overcome this
limitation is to use devices to enhance the effect of the health state
(e.g., spectacles to replicate different severities of visual impair-
ment). Such simulation techniques can help the respondents to
better imagine life in the health state; however, they are not ap-
plicable to all disease states. Deliberation and adaptation tech-
niques explicitly encourage respondents to consider broader life
aspects in relation to the health state. The deliberation approach
may replicate the way in which “real-life” decisions are made,
whereas adaptation exercises inform the respondents about the
possibility of adapting to an impaired health state over time.
Discussion
This review aimed to gain an understanding of the methods cur-
rently being used to inform the general population when valuing
health states. Conventionally, health states in valuation studies
tend to be described as varying levels of a limited number of dif-
ferent domains. Theymay not, however, provide enough sensitiv-
ity for general population respondents to familiarize themselves
with the health state and provide a meaningful valuation. By pro-
viding additional information, alongside the descriptions, focus-
ing illusion effect—an inattention to broad life domains and over-
estimation of the emotional impact of an event [13]—may be
reduced. Specifically, general population respondentsmay dispro-
portionately focus on certain activities that could be negatively
affected by the impaired health state and ignore other aspects of
life (e.g., personal and spiritual relationships) that may be unaf-
fected by a changed state of health [14]. These influences could
cause respondents to under- or overestimate their HSUVs, biasing
the outcome of a CUA. Although informing the respondents does
not ensure that all start at exactly the same knowledge point, it
should eliminate complete unawareness of the health state.
This review’s ability to determine themost effectivemethod to
inform the general population is limited because most studies did
not include either independent control groups or pre- and post-
test measurements. Without these specific components, the im-
pact of the information on HSUVs cannot be directly assessed.
Only seven studies included controls; of these, three used patients
as “controls”. Of the seven, only studies 10 and 14 included pre-
and posttest measurements (Table 1). As a result, the impact of
informing the general population on their HSUVs cannot be gen-
eralized in this review. Although both of these studies revealed
that the informed HSUVs were not significantly different fromthose of the controls, these are too few from which to draw a
meaningful conclusion.
The majority of studies had general population respondents
value disease-specific health states rather than generic ones. The
use of disease-specific states may enable respondents to better
imagine the impact of the health state on their QOL; however, this
prevents comparison across diseases. As a result, it would bemore
beneficial to understand how to best inform them about generic
health states [4–6]. However, there is concern that the value cur-
rently attached to the QOL of these generic states may be deter-
mined by unengaged and uninformed members of the general
population. Future work could involve the recalculation of tariffs
(e.g., EuroQoL 5D) that are currently being used to generate popu-
lation HSUVs for use in economic evaluation with respondents
who are informed about the health states that they are valuing to
assess whether there was a difference between the uninformed
and informed HSUVs. By doing this, wider use of the QALY as a
health outcomesmeasuremay be established [15]. Anotherway to
inform the general population is to provide them with patient
HSUVs; this was not explored in any of the reviewed studies. The
drawback of this method is that patient HSUVs needs to be col-
lected at different time points to describe a series of events, in-
cluding at disease onset, during adaptation, and after a period of
time livingwith the condition [10]. For this approach, however, the
QALY model will need to be reconsidered. By calculating individ-
ual QALYs for each time point, duration and QOL can no longer be
regarded as utility independent. This could significantly affect the
standard practice of using valuation sets in economic evaluation
of health-care technologies.
Despite the recommendation to use informed general popula-
tion values in decision making [4–6], this review demonstrates
hat relatively few studies have aimed at informing the general
opulation about the health states that they are being asked to
alue; this may be a result of there being no guidance on how to
onstruct HSUVs of this type. Due to limitationswithin the designs
f the reviewed work (i.e., absence of independent control groups
r pre- and posttest measurements), there is no clear indication of
hich methods for informing respondents are appropriate and
hether these methods would vary for different disease states.
hemajority of the reports, however, indicated that informing the
espondents significantly affected their opinions of the health
tates and hence their HSUVs. This suggests that the utilities that
re currently used to guide health-care resource allocation deci-
ions may not represent the general populations’ preferences for
he health states. This could potentially result in decisions that do
ot maximize societal health benefits. Given these important pol-
cy implications, further research to develop an appropriate
ethod for informing general population values is needed.
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